



Fig. 2B




Fig. 2C

V




Fig. 3A




Fig. 3B




Fig. 4A




Fig. 4B









Fig. 4C




















Fig. 8




Fig. 9



Fig. 10








Fig. 11











CONTROL

-2

Fig. 12D

CONTROL (b)








Fig. 13D





Fig. 14










Fig. 16










| MICRO-ORGANISMES   |                                 |
|--|---------------------------------|
| Feuille facultative relative au micro-organisme mentionné au page 4 ligne 15 de la description   |                                 |
| A. IDENTIFICATION DU DÉPÔT   |                                 |
| Collection Nationale de Cultures de Micro-organismes   |                                 |
| Adresse de l'institution de dépôt (y compris le code postal et le pays)  |                                 |
| 28 rue du Docteur Roux, 75724 PARIS CEDEX 15   |                                 |
| Date du dépôt 18 avril 1996  | N° d'ordre I-1694               |
| B. INDICATIONS SUPPLÉMENTAIRES (à ne remplir que si nécessaire). Une feuille séparée est jointe pour la suite de ces renseignements  |                                 |
| "En ce qui concerne les désignations dans lesquelles un brevet européen est demandé, un échantillon du micro-organisme déposé ne ser accessible, jusqu'à la publication de la mention de la délivrance du brevet européen ou jusqu'à la date à laquelle la demande sera rejetée, retirée ou réputée retiré, que par la remise d'un échantillon à un expert désigné par le requérant. (règle 28.4) de la CBE)". |                                 |
| C. ÉTATS DÉSIGNÉS POUR LESQUELS LES INDICATIONS SONT DONNÉES (si les indications ne sont pas données pour tous les États désignés)   |                                 |
| EUROPE NOUVELLE-ZELANDE  |                                 |
| AUSTRALIE ETATS-UNIS D'AMERIQUE CANADA   |                                 |
| JAPON  |                                 |
| TO THE TOUR DELIBERT OF DADINES  | A no complia que si mésosociro) |
| D. INDICATIONS FOURNIES SÉPARÉMENT (à ne remplir que si nécessaire)  |                                 |
| Les indications énumérées ci-après seront soumises ultérieurement au Bureau international (spécifier la nature générale des indications p. ez., "No d'ordre du dépôt")   |                                 |
| E.   La présente feuille à été reçue avec la demande internationale lorsque celle-ci a été déposée (à vérifier par l'office récepteur)   |                                 |
| (Fonctionnaire autorisé)   |                                 |
| Date de réception (en provenance du déposant) par le Bureau International  |                                 |
| C. BEDNARICK   |                                 |
| (Fonctionnaire autorisé)   |                                 |
|  |                                 |

F rmulaire PCT/RO/134 (Janvier 1981)



F rmulaire PCT/RO/134 (Janvier 1981)

Fig. 19

FIGURE 20

0.0325


CS90.0

D.125c/d

P/9570


P/95.0


Optokinetic performance in RCS rats with an immortalised RPE LD7.4 cell line transplant in both eyes



IGURE 21

## sham






LD7.4 #1


LD7.4 #2

## Optokinetic performance in RCS rats with Human RPE cell transplants 116 and 7


Ĭ.

• At 7 weeks of age (approx. 3-4 weeks post trasnplantation





b.At 14 weeks of age(approx. 10-11 weeks)post trasnplantation




Human RPE #1

control


Human RPE #2


sham

A



 $\mathcal{B}$ 





B

FIGURE 26




FIGURE 27






FIG. 28

• 1


## A: Head tracking apparatus as viewed from above.




## B: Head tracking 10 weeks postoperative.




C: Head tracking 20 weeks postoperative.



Grating frequency (cycles/degree)



E: Statistical significance map of hRPE-7 versus Sham







FIG. 31






FIG. 32